Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia

Schizophrenia Research

Volumn 128, Issue 1-3, 2011, Pages 127-135

  Hatta, Kotaro ^a   Otachi, Taro ^b   Sudo, Yasuhiko ^c   Hayakawa, Tatsuro ^d   Ashizawa, Yuko ^d   Takebayashi, Hiroshi ^e   Hayashi, Naoki ^f   Hamakawa, Hiroshi ^g   Ito, Shin ^h   Nakase, Reiko ⁱ   Usui, Chie ^a   Nakamura, Hiroyuki ^j   Hirata, Toyoaki ^k   Sawa, Yutaka ^g  

^a JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

^b Gunma Psychiatric Medical Center   (Japan)

^c Tosa Hospital   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e Saitama Prefectural Psychiatric Hospital   (Japan)

^f TOKYO METROPOLITAN MATSUZAWA HOSPITAL   (Japan)

^g Sawa Hospital   (Japan)

^h Tokyo Musashino Hospital   (Japan)

ⁱ Mie Pref General Medical Center   (Japan)

^j KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^k Shizuoka Psychiatric Medical Center   (Japan)

more..

Author keywords

Clinical global impressions scale; Clinical trial; Emergency; Olanzapine; Risperidone; Treatment response

Indexed keywords

BENZODIAZEPINE; BROMAZEPAM; BROTIZOLAM; ESTAZOLAM; ETHYL LOFLAZEPATE; FLUNITRAZEPAM; HALOPERIDOL; LORAZEPAM; NITRAZEPAM; OLANZAPINE; RISPERIDONE;

ACUTE DISEASE; ADULT; ARTICLE; BODY MASS; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERPROLACTINEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY;

EID: 79955474605     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2011.02.011     Document Type: Article

References (22)

1. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162(3):441-449.
2. Ascher-Svanum H., Nyhuis A.W., Faries D.E., Kinon B.J., Baker R.W., Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr. Bull. 2008, 34(6):1163-1171.
3. Bigos K.L., Pollock B.G., Coley K.C., Miller D.D., Marder S.R., Aravagiri M., Kirshner M.A., Schneider L.S., Bies R.R. Sex, race, and smoking impact olanzapine exposure. J. Clin. Pharmacol. 2008, 48(2):157-165.
4. Breier A., Meehan K., Birkett M., David S., Ferchland I., Sutton V., Taylor C.C., Palmer R., Dossenbach M., Kiesler G., Brook S., Wright P. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch. Gen. Psychiatry 2002, 59(5):441-448.
5. Correll C.U., Malhotra A.K., Kaushik S., McMeniman M., Kane J.M. Early prediction of antipsychotic response in schizophrenia. Am. J. Psychiatry 2003, 160(11):2063-2065.
6. Emsley R., Rabinowitz J., Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am. J. Psychiatry 2006, 163(4):743-745.
7. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, US Dept of Health, Education, and Welfare, Bethesda.
8. Hatta K., Takahashi T., Nakamura H., Yamashiro H., Endo H., Fujii S., Fukami G., Masui K., Asukai N., Yonezawa Y. Abnormal physiological conditions in acute schizophrenic patients on emergency admission: dehydration, hypokalemia, leukocytosis and elevated serum muscle enzymes. Eur. Arch. Psychiatry Clin. Neurosci. 1998, 248(4):180-188.
9. Hatta K., Sato K., Hamakawa H., Takebayashi H., Kimura N., Ochi S., Sudo Y., Asukai N., Nakamura H., Usui C., Kawabata T., Hirata T., Sawa Y. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophr. Res. 2009, 113(1):49-55.
10. Inada T. Evaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to its Usage 1996, Seiwa Shoten Publishers, Tokyo.
11. Jones S.H., Thornicroft G., Coffey M., Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br. J. Psychiatry 1995, 166(5):654-659.
12. Kane J.M., Leucht S. Unanswered questions in schizophrenia clinical trials. Schizophr. Bull. 2008, 34(2):302-309.
13. Kane J.M., Leucht S., Carpenter D., Docherty J.P. Optimizing pharmacologic treatment of psychotic disorders. J. Clin. Psychiatry 2003, 64(Suppl. 12):1-100.
14. Kay S.R., Opler L.A., Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Rating Manual 1991, Multi-Health System Inc, Toronto.
15. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Sniadecki J.L., Kane J.M. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr. Res. 2008, 102(1-3):230-240.
16. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Zhou W., Kapur S., Kane J.M. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010, 35(2):581-590.
17. Leucht S., Engel R.R. The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacology 2006, 31(2):406-412.
18. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R.R. What does the PANSS mean?. Schizophr. Res. 2005, 79(2-3):231-238.
19. Leucht S., Busch R., Kissling W., Kane J.M. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J. Clin. Psychiatry 2007, 68(3):352-360.
20. Leucht S., Shamsi S.A., Busch R., Kissling W., Kane J.M. Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. Schizophr. Res. 2008, 101(1-3):312-319.
21. Leucht S., Davis J.M., Engel R.R., Kissling W., Kane J.M. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr. Scand. 2009, 119(Suppl. 438):7-14.
22. Ng C.H., Chong S.A., Lambert T., Fan A., Hackett L.P., Mahendran R., Subramaniam M., Schweitzer I. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int. Clin. Psychopharmacol. 2005, 20(3):163-168.